Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

References

• Gatchel RJ, McGeary DD, McGeary CA, et al. Interdisciplinary chronic pain management: past, present, and future. Am Psychologist. 2014;69:119.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.
   PubMedGoogle Scholar
• Smith HS, Kirsh KL, Passik SD. Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag. 2009;5(5):287–300.
   PubMedGoogle Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004 Dec 1;112(3):372–380.
   PubMed Web of Science ®Google Scholar
• Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther. 2001;1:183–205.
   Google Scholar
• Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129–180.
   PubMed Web of Science ®Google Scholar
• Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–1385.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. Jama. 2015;313:2456–2473.
   PubMed Web of Science ®Google Scholar
• Serpell M, Ratcliffe S, Hovorka J, et al. A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18:999–1012.
   PubMed Web of Science ®Google Scholar
• Meng H, Johnston B, Englesakis M, et al. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesthesia Analg. 2017;125:1638–1652.
   PubMed Web of Science ®Google Scholar
• Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report. Eur J Intern Med. 2018;49:7–11.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167–179.
   PubMed Web of Science ®Google Scholar
• Wiese B, Wilson-Poe AR. Emerging evidence for cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3:179–189.
   PubMedGoogle Scholar
• Bradford AC, Bradford WD, Abraham A, et al. Association between US state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med. 2018;178:667–672.
   PubMed Web of Science ®Google Scholar
• Birnbaum A. How high can patients get on CBD? Epilepsy Curr. 2019 Sep 16:1535759719874408.
   Web of Science ®Google Scholar
• Dill JL, Kurkowski A. CBD: considerations for use within the health system. Hosp Pharm. 2019. doi:10.1177/0018578719873870.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Guimarães FS, Campos AC, et al. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018;9:2009. doi:10.3389/fimmu.2018.02009.
   PubMed Web of Science ®Google Scholar
• Dragone D, Prarolo G, Vanin P, et al. Crime and the legalization of recreational marijuana. J Econ Behav Organiz. 2019 Mar;1(159):488–501.
   Web of Science ®Google Scholar
• Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under US law. Epilepsy Behav. 2017 May;1(70):288–291.
   Web of Science ®Google Scholar
• Malone T, Gomez K. Hemp in the United States: a case study of regulatory path dependence. Appl Econ Perspect Policy. 2019 Mar 8;41(2):199–214.
   Web of Science ®Google Scholar
• Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10. doi:10.3389/fpls.2019.00697.
   PubMed Web of Science ®Google Scholar
• Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018 Jul 1;3(1):152–161.
   PubMedGoogle Scholar
• Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019 Jan 25;9(2):191–203.
   PubMed Web of Science ®Google Scholar
• Ren Y, Whittard J, Higuera-Matas A, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009 Nov 25;29(47):14764–14769.
   PubMed Web of Science ®Google Scholar
• Moeller-Bertram T, Schilling J, Hughes C, et al. (360) can CBD reduce the use of pain medication? Lessons from a survey in a pain clinic environment. J Pain. 2019 Apr 1;20(4):S64.
   Web of Science ®Google Scholar
• Hurd YL, Yoon M, Manini AF, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015 Oct 1;12(4):807–815.
   PubMed Web of Science ®Google Scholar
• Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019 May 21. doi:10.1176/appi.ajp.2019.18101191
   PubMed Web of Science ®Google Scholar
• Haroutounian S, Ratz Y, Ginosar Y, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain. Clin J Pain. 2016 Dec 1;32(12):1036–1043.
   PubMed Web of Science ®Google Scholar
• Knopf A. CBD may help prevent relapse in abstinent heroin addicts. Alcohol Drug Abuse Weekly. 2019 Jun 3;31(22):3–4.
   Google Scholar
• Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46:207–218.
   PubMed Web of Science ®Google Scholar
• Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2:139–154.
   PubMedGoogle Scholar
• World Health Organization. Cannabidiol (CBD) pre-review report agenda item 5.2. Expert Committee on Drug Dependence Thirty-ninth Meeting; Geneva; 2017.
   Google Scholar
• Lau N, Sales P, Averill S, et al. A safer alternative: cannabis substitution as harm reduction. Drug Alcohol Rev. 2015;34(6):654–659.
   PubMed Web of Science ®Google Scholar
• Curran HV, Freeman TP, Mokrysz C, et al. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293.
   PubMed Web of Science ®Google Scholar
• Zehra A, Burns J, Liu CK, et al. Cannabis addiction and the brain: a review. FOCUS J Am Psychiatr Assoc. 2019;17(2):169–182.
   Google Scholar
• Simpson AK, Magid V. Cannabis use disorder in adolescence. Child Adolesc Psychiatr Clin N Am. 2016;25(3):431–443.
   PubMed Web of Science ®Google Scholar